Evidence for target-specific outgrowth from subpopulations of grafted human dopamine neurons

Microscopy Research and Technique

Volumn 54, Issue 5, 2001, Pages 287-297

  Strömberg, Ingrid ^a   Törnqvist, Nina ^a   Johansson, Saga ^a   Bygdeman, Marc ^a   Almqvist, Per M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dopamine; Human xenografts; MPTP; Parkinson's disease

Indexed keywords

AMINES; AMINO ACIDS; NEURODEGENERATIVE DISEASES; NEURONS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; DOPAMINE; DOPAMINE NEURONS; FUNCTIONAL RECOVERY; HUMAN XENOGRAFT; NERVE FIBERS; PARKINSON'S DISEASE; STRIATUM; TETRAHYDROPYRIDINES; TYROSINE HYDROXYLASE;

ANIMALS;

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SUBPOPULATION; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FEMALE; FETUS; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MESENCEPHALON; NERVE FIBER DEGENERATION; NERVE FIBER GROWTH; NERVE PROJECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REINNERVATION;

ANIMALIA;

EID: 0035450218     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jemt.1141     Document Type: Article

References (48)

1. Berglund E, Almqvist P, Lindroos H, Carlsson S, Stigbrand T. 1987. Antigenic pattern of human brain glycoproteins as described by monoclonal antibodies. J Neurochem 48:809-815.
2. Bezard E, Gross CE, Fournier MC, Dovero S, Bloch B, Jaber M. 1999. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol 155:268-273.
3. Björklund L, Vidai N, Strömberg I. 1998. Lazaroid-enhanced survival of grafted dopamine neurons does not increase target innervation. NeuroRep 9:2815-2819.
4. Boyce S, Kelly E, Reavill C, Jenner P, Marsden C. 1984. Repeated administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurons. Biochem Pharmacol 33:1747-1752.
5. Broadwell RD, Charlton HM, Elbert PS, Hickey WF, Shirazi Y, Villegas JC, Wolf AL. 1991. Allografts of CNS tissue possess a blood-brain barrier. II Angiogenesis in solid tissue and cell suspension grafts. Exp Neurol 112:1-28.
6. Burns R, Chieuh C, Markey S, Ebert M, Jacobowitz D, Kopin I. 1983. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahyropyridine. Proc Natl Acad Sci USA 80:4546-4550.
7. Dahlström A, Fuxe K. 1964. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of the brain stem neurons. Acta Physiol Scand (Suppl 232) 62:1-55.
8. Di Loreto S, Florio T, Capozzo A, Napolitano A, Adorno D, Scarnati E. 1996. Transplantation of mesencephalic cell suspension in dopamine denervated striatum of the rat. Exp Neurol 138:318-326.
9. Fisher LJ, Young SJ, Tepper JM, Groves PM, Gage FH. 1991. Electrophysiological characteristics of cells within mesencephalon suspension grafts. Neuroscience 40:109-122.
10. Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK. 1994. Studies on species sensitivity to the dopamineric neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin. Part I: Systemic administration. J Pharmacol Exp Ther 270:1000-1007.
11. Granholm A-C, Curtis M, Diamond DM, Branch BJ, Heman KL, Rose GM. 1996. Development of an intact blood-brain barrier in brain tissue transplants is dependent on the site of transplantation. Cell Transplant 5:305-314.
12. 2 receptor, tyrosine hydroxylase and calbinding immunoreactivity. J Comp Neurol 362:400-410.
13. Hansson O, Castilho RF, Kaminski Schierle GS, Kalrsson J, Nicotera P, Leist M, Brundin P. 2000. Additive effects of caspase inhibitor and lazaroid on the survival of transplanted rat and human embryonic dopamine neurons. Exp Neurol 164:102-112.
14. Haque NSK, LeBlanc CJ, Isacson O. 1997. Differential dissection of the rat E16 ventral mesencephalon and survival and reinnervation of the 6-OHDA-lesioned striatum by a subset of aldehyde dehydrogenase-positive TH neurons. Cell Transplant 6:239-248.
15. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. 1984. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467-469.
16. Helt CE, Hoeraing GR, Albeck DS, Gerhardt GA, Reyland ME, Quissel DO, Strömberg I, Granholm A-C. 2001. Neuroprotection of neural grafts with a trophic factor/caspase inhibitor cocktail. Exp Neurol (in press).
17. Hudson J, Bickford P, Johansson M, Hoffer BJ, Strömberg I. 1994. Target and neurotransmitter specificity of fetal central nervous system transplants: Importance for functional reinnervation. J Neurosci 14:283-290.
18. Johnson D, de C Nogueira-Araujo G. 1981. A simple method of reducing the fading of immunofluorescence during microscopy. J Immunol Methods 43:349-350.
19. Jossan SS, Sakurai E, Oreland L. 1989. MPTP toxicity in relation to age, dopamine uptake and MAO-B activity in two rodent species. Pharmacol Toxicol 64:314-318.
20. Klausen BS, Swensin RS, Zimmer J, Castro AJ. 1992. Fetal neocortical transplants in rats: blood-brain barrier development and partial permeability to IgG in long-surviving grafts. Restor Neurol Neurosci 4:393-400.
21. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJG, Mufson EJ, Sandberg PR, Hauser RA, Smith DA, Nauert GM, Perl DP, Olanow CW. 1995. Neuropathological evidence of graft survival and striatal reinnervation after transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 332:1118-1124.
22. Kordower JH, Rosenstein JM, Collier TJ, Burke MA, Chen E-Y, Li JM, Martel L, Levey AE, Mufson EJ, Freeman TB, Olanow CW. 1996. Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol 370:203-230.
23. Kordower JH, Freeman TB, Chen EY, Mufson EJ, Sandberg PR, Hauser RA, Snow B, Olanow CW. 1998. Fetal nigral grafts survive and mediate clinical benfit in a patient with Parkinson's disease. Mov Disord 13:383-93.
24. Langston JW, Irwin I, Langston EB, Forno LS. 1984. Pargyline prevents MPTP-induced parkinsonism in primates. Science 225:1480-1482.
25. Mahalik TJ, Hahn WE, Clayton GH, Owens GP. 1994. Programmed cell death in developing grafts of fetal substantia nigra. Exp Neurol 129:27-36.
26. Markey SP, Johanessen JN, Chieu CC, Burns RS, Herkenham MA. 1984. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311:464-466.
27. Nakano Y, Takei K, Toya S, Tsukada Y, Ghandour S, Kohsaka S. 1989. Mosaic reconstitution of blood vessels in mouse neonatal tissue tansplanted into the third ventricle of rat brain. Brain Res 496:336-340.
28. Nakao N, Frodl EM, Duan W-M, Widner H, Brundin P. 1994. Lazaroids improve the survival of grafted rat embryonic dopamine neurons. Proc Natl Acad Sci USA 91:12408-12412.
29. Pifl C, Schingnitz G, Hornykiewicz O. 1991. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridme on regional distribution of brain momoamines in the rhesus monkey. Neuroscience 44:591-605.
30. Riachi NJ, Behmand RA, Harik SI. 1991. Correlation of MPTP neurotoxicity in vivo with oxidation of MPTP by the blood-brain barrier in vitro in five rat strains. Brain Res 555:19-24.
31. Rioux L, Gaudin DP, But LK, Grégoire L, DiPaolo T, Bédard PJ. 1991. Correlation of functional recovery after a 6-hydroxydopamine lesion with survival of grafted fetal neurons and release of dopamine in the striatum of the rat. Neuroscience 40:123-131.
32. 3H]GABA in intraparenchymal fetal CNS tissue grafts. Exp Neurol 142:66-79.
33. Saghal A, Andrews J, Biggins J, Candy J, Edwardson J, Keith A, Turner J, Wright C. 1984. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects locomoter activity without producing a nigrostriatal lesion in the rat. Neurosci Lett 48:179-184.
34. Savasta M, Mennicken F, Chritin M, Abrous DN, Feuerstein C, Le Moal M, Herman J. 1992. Intrastriatal dopamine-rich implants reverse the changes in dopamine D2 receptor densities caused by 6-hydroxydopaine lesion of the nigrostriatal pathway in rats: An autoradiographic study. Neuroscience 46:729-738.
35. Schmidt-Kastner R, Meller D, Bellander B-M, Strömberg I, Olson L, Ingvar M. 1993. A one-step immunohistochemical method for detection of blood-brain barrier disturbances for immunoglobulins in lesioned rat brain with special reference to false-positive labelling in immunohistochemistry. J Neurosci Methods 46:121-132.
36. Seaton TA, Cooper JM, Schapira AHV. 1997. Free raadical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res 777:110-118.
37. Strömberg I, Johnson S, Hoffer B, Olson L. 1985. Reinnervation of dopamine-denervated striatum by substantia nigra transplants. Immunocytochemical and electrophysiological correlates. Neuroscience 14:981-998.
38. Strömberg I, Bygdeman M, Almqvist P. 1992. Target-specific outgrowth from human mesencephalic tissue grafted to cortex or ventricle of immunosuppressed rats. J Comp Neurol 315:445-456.
39. Strömberg I, Kehr J, Andbjer B, Fuxe K. 2000. Fetal ventral mecencephalic grafts functionally reduce the dopamine D2 receptor supersensitivity in partially dopamine reinnervated host striatum. Exp Neurol 164:154-165.
40. Sundström E, Strömberg I, Tsutsumi T, Olson L, Jonsson G. 1987. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57 BL/6 mice. Comparision with three other strains of mice. Brain Res 405:26-38.
41. Törnqvist N, Björklund L, Strömberg I. 2001. Evidence for target-specific outgrowth from subpopulations of grafted dopaminergic nerons. A retrograde study using in oculo and intracranial grafting. Exp Neurol 169:329-339.
42. Ungerstedt U. 1968. 6-Hydroxydopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5:107-110.
43. Ungerstedt U, Arbuthnott G. 1970. Quantitative recording of rotational behaviour in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24:485-493.
44. Ungerstedt U, Herrera-Marschitz M. (1981) Behavioral pharmacology of dopamine receptor mechanisms. In: Stjärne L, Hedqvist P, Lagerkrantz H, Wenmalm A, editors. Chemical neurotransmission: 75 years. New York: Academic Press; p 482-494.
45. Walters RA, Jackson-Lewis V, Sadik A, Fahn S. 1984. Failure to produce chronic parkinsonism with MPTP in rats. Biogenic Amines 1:297-302.
46. Wictorin K, Brundin P, Sauer H, Lindvall O, Björklund A. 1992. Long distance directed axonal growth from human dopaminergic mesencephalic neuroblasts implanted along the nigrostriatal pathway in 6-hydroxydopamine lesioned adult rats. J Comp Neurol 323:475-494.
47. Zawada WM, Kirschman DL, Cohen JJ, Heidenreich KA, Freed CR. 1996. Growth factors rescue embryonic dopamine neurons from programmed cell death. Exp Neurol 146:60-67.
48. Zuddas A, Corsini G, Barker J, Kopin I, di Porzio U. 1991. Specific reinnervation of lesioned mouse striatum by grafted mesencephalic dopaminergic neurons. Eur J Neurosci 3:72-85.